Skip to main content

Rabbit Recombinant Monoclonal LOXL2 antibody. Suitable for IP, WB and reacts with Human samples.

Be the first to review this product! Submit a review

Images

Western blot - Anti-LOXL2 antibody [EPR23035-105] (AB260046), expandable thumbnail
  • Immunoprecipitation - Anti-LOXL2 antibody [EPR23035-105] (AB260046), expandable thumbnail
  • Western blot - Anti-LOXL2 antibody [EPR23035-105] (AB260046), expandable thumbnail

Key facts

Isotype
IgG
Host species
Rabbit
Storage buffer

pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Form
Liquid
Clonality
Monoclonal

Immunogen

  • The exact immunogen used to generate this antibody is proprietary information.

Abcam Recommends

Reactivity data

Select an application
Product promiseTestedExpectedPredictedNot recommended
IPFlow CytWBIHC-PICC/IF
Human
Tested
Not recommended
Tested
Not recommended
Not recommended

Tested
Tested

Species
Human
Dilution info
1/30
Notes

-

Not recommended
Not recommended

Species
Human
Dilution info
-
Notes

-

Tested
Tested

Species
Human
Dilution info
1/1000
Notes

-

Not recommended
Not recommended

Species
Human
Dilution info
-
Notes

-

Not recommended
Not recommended

Species
Human
Dilution info
-
Notes

-

Associated Products

Select an associated product type

5 products for Alternative Product

Target data

Function

Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine) (PubMed:27735137). Acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation (PubMed:27735137). Shows no activity against histone H3 when it is trimethylated on 'Lys-9' (H3K9me3) or 'Lys-27' (H3K27me3) or when 'Lys-4' is monomethylated (H3K4me1) or dimethylated (H3K4me2) (PubMed:27735137). Also mediates deamination of methylated TAF10, a member of the transcription factor IID (TFIID) complex, which induces release of TAF10 from promoters, leading to inhibition of TFIID-dependent transcription (PubMed:25959397). LOXL2-mediated deamination of TAF10 results in transcriptional repression of genes required for embryonic stem cell pluripotency including POU5F1/OCT4, NANOG, KLF4 and SOX2 (By similarity). Involved in epithelial to mesenchymal transition (EMT) via interaction with SNAI1 and participates in repression of E-cadherin CDH1, probably by mediating deamination of histone H3 (PubMed:16096638, PubMed:24414204, PubMed:27735137). During EMT, involved with SNAI1 in negatively regulating pericentromeric heterochromatin transcription (PubMed:24239292). SNAI1 recruits LOXL2 to pericentromeric regions to oxidize histone H3 and repress transcription which leads to release of heterochromatin component CBX5/HP1A, enabling chromatin reorganization and acquisition of mesenchymal traits (PubMed:24239292). Interacts with the endoplasmic reticulum protein HSPA5 which activates the IRE1-XBP1 pathway of the unfolded protein response, leading to expression of several transcription factors involved in EMT and subsequent EMT induction (PubMed:28332555). Involved in E-cadherin repression following hypoxia, a hallmark of EMT believed to amplify tumor aggressiveness, suggesting that it may play a role in tumor progression (PubMed:20026874). When secreted into the extracellular matrix, promotes cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin (PubMed:20306300). Acts as a regulator of sprouting angiogenesis, probably via collagen IV scaffolding (PubMed:21835952). Acts as a regulator of chondrocyte differentiation, probably by regulating expression of factors that control chondrocyte differentiation (By similarity).

Alternative names

Lysyl oxidase homolog 2, Lysyl oxidase-like protein 2, Lysyl oxidase-related protein 2, Lysyl oxidase-related protein WS9-14, LOXL2

Recommended products

Rabbit Recombinant Monoclonal LOXL2 antibody. Suitable for IP, WB and reacts with Human samples.

Key facts

Isotype
IgG
Form
Liquid
Clonality
Monoclonal
Immunogen
  • The exact immunogen used to generate this antibody is proprietary information.
Clone number
EPR23035-105
Purification technique
Affinity purification Protein A
Concentration
Loading...

Storage

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Notes

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

3 product images

  • Western blot - Anti-LOXL2 antibody [EPR23035-105] (ab260046), expandable thumbnail

    Western blot - Anti-LOXL2 antibody [EPR23035-105] (ab260046)

    Blocking and dilution buffer: 5% NFDM/TBST.

    LOXL2 is a glycoprotein. Unprocessed LOXL2 (100kDa) and processed LOXL2(70kDa) are observed.

    The expression of LOXL2 is elevated under hypoxia condition.

    The expression profile and molecular weight observed is consistent with what has been described in the literature (PMID:20026874; PMID: 27770022).

    All lanes: Western blot - Anti-LOXL2 antibody [EPR23035-105] (ab260046) at 1/1000 dilution

    Lane 1: Untreated HeLa (human cervix adenocarcinoma epithelial cell), whole cell lysate at 20 µg

    Lane 2: HeLa treated with 2mM Deferoxamine mesylate (DFO) for 24 hours, whole cell lysate at 20 µg

    Secondary

    All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution

    Predicted band size: 87 kDa

    Observed band size: 100 kDa, 70 kDa

    Exposure time: 3min

  • Immunoprecipitation - Anti-LOXL2 antibody [EPR23035-105] (ab260046), expandable thumbnail

    Immunoprecipitation - Anti-LOXL2 antibody [EPR23035-105] (ab260046)

    LOXL2 was immunoprecipitated from 0.35 mg MDA-MB-435S (Human mammary gland ductal carcinoma melanocyte) whole cell lysate with ab260046 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab260046 at 1/500 dilution. VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/1000 dilution.

    Lane 1: MDA-MB-435S (Human mammary gland ductal carcinoma melanocyte) whole cell lysate 10ug

    Lane 2: ab260046 IP in MDA-MB-435S whole cell lysate

    Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of ab260046 in MDA-MB-435S whole cell lysate

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.

    Exposure time: 3 minutes.

    LOXL2 is a glycoprotein. Unprocessed LOXL2 (100kDa) and processed LOXL2(70kDa) are observed. The molecular weight observed is consistent with what has been described in the literature (PMID: 27770022).

    All lanes: Immunoprecipitation - Anti-LOXL2 antibody [EPR23035-105] (ab260046)

    Predicted band size: 87 kDa

    Observed band size: 100 kDa, 70 kDa

  • Western blot - Anti-LOXL2 antibody [EPR23035-105] (ab260046), expandable thumbnail

    Western blot - Anti-LOXL2 antibody [EPR23035-105] (ab260046)

    Blocking and dilution buffer: 5% NFDM/TBST.

    LOXL2 is a glycoprotein. Unprocessed LOXL2 (100kDa) and processed LOXL2(70kDa) are observed.

    The molecular weight observed is consistent with what has been described in the literature (PMID: 27770022).

    Negative control: MCF7 (PMID: 12154058).

    All lanes: Western blot - Anti-LOXL2 antibody [EPR23035-105] (ab260046) at 1/1000 dilution

    Lane 1: MDA-MB-435S (human mammary gland ductal carcinoma melanocyte) whole cell lysate at 20 µg

    Lane 2: MDA-MB-231 (human breast adenocarcinoma epithelial cell) whole cell lysate at 20 µg

    Lane 3: U-87 MG (human glioblastoma-astrocytoma epithelial cell) whole cell lysate at 20 µg

    Lane 4: MCF7 (human breast adenocarcinoma epithelial cell) whole cell lysate at 20 µg

    Secondary

    All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution

    Predicted band size: 87 kDa

    Observed band size: 100 kDa, 70 kDa

    Exposure time: 48s

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com